Business
Ainos Reports First Quarter 2023 Financial Results
Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT
About this update from Ainos, Inc.
[{"type":"text","content":"Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologiesStrategic pivot is underpinned by Ainos' diversified product pipelineSAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2023.Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, \"The first quarter of 2023 marks the beginning of a new chapter for Ainos. As our VOC POCT and VELDONA® technologies progress towards commercialization and COVID-19 becomes endemic, we are pivoting the primary focus of our business away from COVID-19. This strategic shift comes after years of clinical trials and development for our product pipeline, and lays a solid foundation for Ainos' continued long-term growth. Past sales of our COVID-19 test kits have helped us establish key infrastructure and partnerships that will support this transition and the success of our upcoming product offerings.\"\"During the first quarter, we made significant progress in the commercialization of our VELDONA® low-dose oral interferon-alpha (\"IFNα\") formulation, especially in regard to its applications for animal health. We signed an agreement with a Taiwanese pharmaceutical biotech company which granted them exclusive distribution rights for our VELDONA® animal health supplements in Taiwan, marking our entry into the multi-billion-dollar veterinary health market. Meanwhile, our efforts in developing VELDONA® drug candidates for the treatment of various human disease applications continue to progress. In addition, our lead VOC POCT testing candidate, the AI Nose platform-powered Ainos Flora, is currently undergoing clinical trials and is on track to reach commercialization by the end of 2023.\"\"We currently operate primarily in the Taiwan market, which, in contrast to the United States, saw its COVID-19 peak occur last year. This difference in timing has allowed us to make the transition to a commercial endemic market later than our American peers while cont...